$Stock*Shop*Charts*News*Option$

[Tuff-Stuff]

Vivus (VVUS) moves up 4.2% in premarket trading as the dust still clears from a FDA panel that had implications for weight-loss drug Qnexa. Yesterday's roller coaster ride for VVUS may have been a bit of a case of "itchy trader fingers" with the final word on FDA approval for Qnexa still up in the air.